Alnylam Pharmaceuticals Revenue Growth: -3.51%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ALNY Revenue Growth Rankings
| Overall | 23rd percentile | 3374 of 4424 |
| Sector | 24th percentile | 350 of 464 in Healthcare |
| Industry | 35th percentile | 82 of 127 in Biotechnology |
ALNY Revenue Growth Range, Past 5 Years
| Minimum | 3.37% | Sep 2005 |
| Maximum | 1747% | Sep 2004 |
| Average |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ALNY related companies
ALNY News
Listen to $ALNY Q4 2011 earnings call (EPS -0.33 vs est -0.32) - live at 04:30 PM, ondemand after - http://stks.co/2Krr
about 3 days ago by earningscast
about 3 days ago by earningscast
$ALNY Reports Q4 EPS $(0.33) vs $(0.32) Est; Revenues $20.50M vs $20.90M Est
about 3 days ago by Benzinga
about 3 days ago by Benzinga
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Feb 09, 4:00PM Business Wire
Feb 09, 4:00PM Business Wire
Alnylam Scientists Discover Novel Method for Monitoring RNAi Activity in Blood Samples
Feb 09, 8:00AM Business Wire
Feb 09, 8:00AM Business Wire
$ALNY New 52 Week High - Crossed daily highs resistance. Next resistance 13.64 from 11/5/2010.
about 6 days ago by TradeIdeasQuant
about 6 days ago by TradeIdeasQuant
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2011 Financial Results
Feb 02, 4:00PM Business Wire
Feb 02, 4:00PM Business Wire
Alnylam Pharma (ALNY) Receives Notice of Allowance Covering 2G LNP Platform
Jan 30, 8:03AM Street Insider
Jan 30, 8:03AM Street Insider
Rodman & Renshaw Reiterates Outperform, $12 Target on Alnylam Pharmaceuticals
Jan 20, 6:24AM Benzinga
Jan 20, 6:24AM Benzinga
Alnylam (ALNY) Announces Restructuring: Will Cut 33% of Workforce, Sees $4M in Charges
Jan 19, 6:01PM Street Insider
Jan 19, 6:01PM Street Insider
Alnylam (ALNY) Files Patent Infringement Suit Against Tekmira Pharma Over siRNA Molecules
Jan 17, 9:09AM Street Insider
Jan 17, 9:09AM Street Insider
biotech stocks on fire @upsidetrader fanning flames with $ALNY http://stks.co/1vDB $CELG, $AMGN, $GILD, $SPX
about 30 days ago by SFOmag
about 30 days ago by SFOmag
$RXII $GALE $MRNA $ALNY $CYTR $ARWR RIP140 regulation of diabetes Patent8093223 Czech(RXi Pharmaceuticals) http://stks.co/1tyQ
about 31 days ago by biotech
about 31 days ago by biotech
$ALNY rodman comments: these
results represent a key milestone in the advancement of RNAi as a new
class of therapeutis $MRNA $GALE
about 83 days ago by biotech
about 83 days ago by biotech
$MRNA The long wait is finally over: Systemic RNAi delivery has been proven in Man http://stks.co/1DI9 $GALE $RXII $ALNY
about 83 days ago by biotech
about 83 days ago by biotech
$ALNY $MRNA $GALE http://stks.co/15Ih gene mutation that drops heart-attack risk by as much as 88 %
about 93 days ago by biotech
about 93 days ago by biotech
$MRNA Demonstrates That Its Novel UsiRNA Oligonucleotide Abrogates Cytotoxicity Resulting From microRNA-Like Off-Target Activity $ALNY $GSK
about 102 days ago by biotech
about 102 days ago by biotech
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ALNY | 12.15 | -0.90 | -6.90% | 519.17M |
| NETC | 11.47 | -0.55 | -4.58% | 1.31B |
| BIDZ | 0.55 | 0.02 | 3.75% | 10.66M |
| LOCM | 3.08 | -0.11 | -3.45% | 67.76M |
| ACAS | 8.69 | 0.15 | 1.76% | 3.00B |
| AAPL | 493.42 | 0.25 | 0.05% | 458.59B |
| NTES | 48.40 | 0.51 | 1.06% | 6.32B |
| DLTR | 86.83 | -0.07 | -0.08% | 10.59B |
| NWSA | 19.18 | -0.04 | -0.18% | 33.02B |
| CSCO | 19.89 | -0.10 | -0.53% | 106.74B |
